Current Price and Trading Range
As of 8 July 2026, Alembic Pharmaceuticals is trading at ₹831.00, slightly down from the previous close of ₹834.45. The stock’s intraday range has been relatively tight, with a low of ₹824.05 and a high of ₹842.70. This price action reflects a consolidation phase following a recent period of volatility. The 52-week high stands at ₹1,064.70, while the 52-week low is ₹635.30, indicating a wide trading band and potential for both upside and downside movements depending on market catalysts.
Technical Trend Evolution
The technical trend for Alembic Pharmaceuticals has shifted from mildly bearish to sideways, signalling a pause in the previous downward momentum. This transition suggests that the stock is currently in a phase of indecision, with neither buyers nor sellers exerting dominant control. Such sideways movement often precedes a significant directional move, making it crucial to monitor key technical indicators closely.
MACD Analysis
The Moving Average Convergence Divergence (MACD) indicator presents a mixed outlook. On a weekly basis, the MACD is mildly bullish, indicating that short-term momentum is improving and the stock may be poised for a modest rally. However, the monthly MACD remains bearish, reflecting longer-term caution and the possibility of sustained downward pressure. This divergence between weekly and monthly MACD readings highlights the importance of timeframe in technical analysis and suggests that while short-term traders may find opportunities, long-term investors should remain vigilant.
RSI and Momentum Indicators
The Relative Strength Index (RSI) on both weekly and monthly charts currently shows no clear signal, hovering in neutral territory. This lack of extreme readings implies that the stock is neither overbought nor oversold, consistent with the sideways trend. Meanwhile, the Know Sure Thing (KST) indicator is bullish on a weekly basis but bearish monthly, mirroring the MACD’s mixed signals and reinforcing the notion of short-term strength amid longer-term caution.
Bollinger Bands and Moving Averages
Bollinger Bands on the weekly chart are bullish, suggesting that price volatility is expanding upwards and the stock could break out of its recent consolidation. Conversely, the monthly Bollinger Bands are mildly bearish, indicating that the broader trend remains under pressure. Daily moving averages are mildly bearish, signalling that the immediate price action is still weighed down by selling pressure. This combination of signals points to a stock at a technical crossroads, with potential for either a breakout or further consolidation.
Volume and Dow Theory Signals
On-Balance Volume (OBV) readings are bullish on both weekly and monthly charts, indicating that buying volume is outpacing selling volume and supporting the price action. This is a positive sign for momentum traders. Dow Theory assessments also show mild bullishness on both weekly and monthly timeframes, suggesting that the stock’s primary trend may be stabilising or beginning to reverse upwards.
Our current Stock of the Month is out! This Large Cap from Automobiles - Passenger Cars emerged as the single best opportunity from our elite universe. Get the details now!
- - Current monthly selection
- - Single best opportunity
- - Elite universe pick
Comparative Returns and Market Context
Examining Alembic Pharmaceuticals’ returns relative to the Sensex provides further insight into its performance. Over the past week, the stock has gained 0.90%, underperforming the Sensex’s 2.23% rise. However, over the last month, Alembic outperformed significantly with a 12.76% gain compared to the Sensex’s 5.30%. Year-to-date, the stock has declined by 2.03%, but this is less severe than the Sensex’s 8.26% fall, indicating relative resilience.
Longer-term returns reveal a more mixed picture. Over one year, Alembic has declined 16.90%, considerably worse than the Sensex’s 6.31% loss. Over three years, however, the stock has outperformed with a 26.43% gain versus the Sensex’s 19.76%. Five-year returns show a 15.68% loss for Alembic against a robust 47.36% gain for the Sensex, while a ten-year horizon reveals a 43.25% gain for Alembic compared to the Sensex’s 187.41%. These figures highlight the stock’s volatility and the importance of timeframe in assessing performance.
Mojo Score and Rating Upgrade
MarketsMOJO has upgraded Alembic Pharmaceuticals’ Mojo Grade from Sell to Hold as of 2 July 2026, reflecting an improved technical and fundamental outlook. The current Mojo Score stands at 51.0, placing the stock in the Hold category within the Pharmaceuticals & Biotechnology sector. The company is classified as a small-cap, which often entails higher volatility but also potential for growth. This upgrade signals cautious optimism among analysts, suggesting that while the stock is not yet a buy, it has stabilised enough to warrant holding positions rather than exiting.
Technical Summary and Outlook
The overall technical summary for Alembic Pharmaceuticals is one of mixed signals with a tilt towards cautious optimism. Weekly indicators such as MACD, Bollinger Bands, KST, OBV, and Dow Theory suggest mild bullishness and potential for upward momentum. Conversely, monthly indicators remain bearish or mildly bearish, indicating that longer-term trends have yet to confirm a sustained recovery. Daily moving averages’ mildly bearish stance adds to the short-term caution.
Investors should note that the sideways trend reflects a consolidation phase, often a precursor to a significant directional move. The stock’s current price near ₹831.00, well below its 52-week high, offers a potential entry point for those anticipating a technical breakout. However, the mixed signals advise a measured approach, with close monitoring of weekly momentum indicators and volume trends.
Holding Alembic Pharmaceuticals Ltd. from Pharmaceuticals & Biotechnology? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Investor Considerations
For investors, Alembic Pharmaceuticals presents a nuanced opportunity. The recent upgrade to Hold and the mild bullishness in weekly technical indicators suggest that the stock may be stabilising after a period of weakness. However, the persistent bearishness in monthly indicators and the stock’s underperformance over the one- and five-year periods relative to the Sensex counsel prudence.
Those with a medium-term horizon might consider accumulating on dips, particularly if weekly momentum indicators continue to improve and volume supports a breakout. Conversely, long-term investors should weigh the stock’s historical volatility and sector dynamics before increasing exposure. The pharmaceutical and biotechnology sector remains sensitive to regulatory developments, patent outcomes, and broader market sentiment, all of which could influence Alembic’s trajectory.
Conclusion
Alembic Pharmaceuticals Ltd. is currently navigating a complex technical landscape characterised by a shift from bearishness to sideways momentum. Weekly technical indicators provide encouraging signs of mild bullishness, while monthly signals urge caution. The stock’s recent Mojo Grade upgrade to Hold reflects this balanced outlook. Investors should monitor key momentum indicators and volume trends closely, as the stock appears poised for a potential directional move. Given its small-cap status and mixed historical returns, a disciplined approach aligned with risk tolerance is advisable.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →
